1. Introduction {#sec1}
===============

Tardive Dyskinesia (TD) is characterized by involuntary movements, most commonly of orofacial muscles, but also involving muscles of the extremities, trunk and hip ([@bib10]). Faurbye introduced the term "Tardive Dyskinesia" in 1964 ([@bib35]) and noted TD to be more severe and problematic in the United States due to the liberal indications for antipsychotic use, prescribing higher doses of drugs and having a limited choice of antipsychotics ([@bib35]). Tardive dyskinesia (TD) is a severe condition that can affect approximately one out of four patients (25%) receiving dopamine receptor blocking agents (DRBAs), specifically first and second-generation antipsychotics ([@bib6]). According to a study, the prevalence of TD is 32% with typical antipsychotics and 13% with atypical antipsychotics ([@bib11]). The incidence of antipsychotic-induced TD is about 3--5% in young adults as compared to 30% in the middle-aged and elderly after one year of antipsychotic treatment ([@bib21]; [@bib33]). In elderly patients, those receiving DRBA treatment for three months have been noted to have a 29% prevalence of TD as compared to 26--67% of those receiving long-term treatment for six months ([@bib4]).

Chronic antipsychotic-induced dopamine blockade causes an up-regulation and supersensitivity of dopamine receptors resulting in an increase in dopamine neurotransmission in the basal ganglia ([@bib17]). Even after completely stopping the DRBA, TD may persist for years in the patient. In some patients' TD remits entirely even while on DRBAs and in a few patients after stopping the offending agent ([@bib33]). About 33% of patients experienced remission of their TD after two years of discontinuing/stopping DRBA ([@bib33]). Some studies have concluded that longer duration of exposure to DRBAs before discontinuation decreases the chances of remission of TD ([@bib33]). TD has also been related to poor quality of life ([@bib5]) as well as considered as a risk factor concerning mortality ([@bib3]) in patients with psychiatric illness.

Prior studies on TD have been conducted to assess its prevalence ([@bib1]; [@bib8]; [@bib9]; [@bib15]; [@bib34]), risk factors associated with TD severity ([@bib18]; [@bib32]; [@bib38]), and association of TD with different antipsychotics ([@bib7]; [@bib22]; [@bib23]; [@bib26]; [@bib30]). The objective of this study is to analyze the risk factors associated with TD in psychiatric inpatients and assess the differences in hospitalization outcomes regarding the length of stay (LOS) and cost, morbidity and disposition between psychiatric inpatients with versus without TD.

2. Methods {#sec2}
==========

2.1. Data source {#sec2.1}
----------------

We conducted a case-control study, using the Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) database, sponsored by the Agency for Healthcare Research and Quality (AHRQ) ([@bib19]). NIS is the largest database of inpatient stays in the United States and is known to be a valid and reliable data source for epidemiological estimates that involve inpatient care. We used the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes to identify admission with mood disorders, schizophrenia, and other psychotic disorders as the primary diagnosis (DX1).

2.2. Inclusion criteria {#sec2.2}
-----------------------

We analysed the NIS database ([@bib19]) from January 2010 to December 2014 to identify cases-- patients (age 18--70 years) with a primary ICD-9-CM diagnosis code for bipolar disorder, manic type (293.83, 296.00--296.06, 296.10--296.16, 296.40--296.46, 296.60--296.66 or 296.7), bipolar disorder, depressive type (296.50--296.56 or 296.82), bipolar disorder NOS (296.80, 296.89 or 296.7), major depressive disorder (296.20--296.26 or 296.30--296.36), depressive disorder NOS (296.82, 300.4 or 311), mood disorder NOS (293.83, 296.90 or 296.99) or schizophrenia and other psychotic disorders (293.81, 293.82, 295.00--295.05, 295.10--295.15, 295.20--295.25, 295.30--295.35, 295.40--295.45, 295.50--295.55, 295.60--295.65, 295.70--295.75, 295.80--295.85, 295.90--295.95, 297.0--297.3, 297.8--298.4, 298.8 or 298.9) and secondary diagnosis for tardive dyskinesia (TD). We identified patients with TD using the ICD-9-CM diagnosis codes 333.85 (TD); 333.82 (oral-facial dyskinesia); 333.99, 781.0 (akathisia); 333.71 (athetosis); 307.3 (stereotypy); 307.20, 351.8 (facial tics); 333.81 (blepharospasm). Controls included the patients with a primary diagnosis of mood disorders or schizophrenia and other psychotic disorders as mentioned in the inclusion criteria for cases, and without a secondary diagnosis of TD. We performed a retrospective analysis to derive a control cohort that was matched with the cases on age.

2.3. Variables {#sec2.3}
--------------

Demographic variables examined in this study included age, gender, race, health insurance and median household income ([@bib25]). Comorbidities are considered coexisting conditions to primary psychiatric diagnoses under this study ([@bib25]). AHRQ comorbidity software of the HCUP was applied to identify comorbidities in the patient records using ICD-9-CM codes-- diabetes (249.00--249.31, 250.00--250.33 or 648.00--648.04), hypertension (401.1, 401.9, 642.00--642.04, 401.0, 402.00--405.99, 437.2, 642.10--642.24 or 642.70--642.94), obesity (278.0, 278.00, 278.01, 278.03, 649.10--649.14, 793.91, V85.30-V85.39, V85.41-V85.45 or V85.54), tobacco use (305.1 or 989.84), alcohol abuse (291.0--291.3, 291.5, 291.8, 291.81, 291.82, 291.89, 291.9 or 303.00--303.93, 305.00--305.03) and drug abuse (292.0, 292.82--292.89, 292.9, 304.00--304.93, 305.20--305.93, 648.30--648.34).

To compare the differences in psychiatric hospitalization outcomes of patients with and without TD, the outcome variables of interest included the severity of illness that measures the loss of body functions, LOS, total charges, and disposition of patient. The All Patient Refined DRGs (APR-DRGs) and 3M Health Information Systems software were used to measure the severity of illness subclass ([@bib25]). In the NIS, we defined the LOS as the number of nights the patient was hospitalized for a particular primary diagnosis (DX1) ([@bib25]). Total charges does not include professional fees and non-covered charges. If the source provided total charges with professional fees, then these fees were removed from the charges during data processing ([@bib25]).

2.4. Statistical analysis {#sec2.4}
-------------------------

All statistical analyses was done on SPSS version 23 (IBM Corp. Armonk, NY). Discharge weight (DISCWT) variable in the NIS were applied during the analysis to obtain nationally representative inpatient data. In these analyses, the Pearson Chi-squared test was used for categorical data to compare characteristics of patients with TD versus without TD. The mean LOS and cost differences between both groups was analyzed using a univariate general linear model. A multivariable logistic regression model was used to evaluate TD for several demographic variables, comorbidities and hospital outcomes with patients without TD as the reference category. Separate models were run for each outcome. We applied discharge weights in all regression models and adjusted for age, gender, race, income, and comorbidities. We also examined the effect of TD on the LOS and total charges of inpatient care for patients with mood disorders and schizophrenia. General linear multiple regression analysis was used to estimate the association of TD with the LOS and total charges, with control for demographic variables and disease morbidity. Due to the large sample size and multiple comparisons of data, statistical significance was set a priori at \<.001 for all analyses.

2.5. Ethical approval {#sec2.5}
---------------------

Our database did not contain patients\' personally identifiable information. KEYID variable in the NIS was used to conceal patient identity and prevent identification of patient health information. Also, the diagnostic information in the NIS are identified using the ICD-9-CM codes. Therefore, analysis on a de-identified NIS data does not require Institution Review Board (IRB) approval.

3. Results {#sec3}
==========

3.1. Sample characteristics {#sec3.1}
---------------------------

Our study included 77,022 inpatient admissions for mood disorders, schizophrenia and other psychotic disorders, and 38,382 patients with a secondary diagnosis of TD. The mean age of the study population was 47.2 years (±14.13) and the study sample comprised of patients in following age groups: 18--30 (16.9%), 31--40 (14.3%), 41--50 (21.1%), 51--60 age (28.0%) and 61--70 (19.7%). There were 50.6% females, and regarding racial distribution, the majority were Caucasian (74.7%) followed by African American (12.9%) and Hispanic (7.9%).

About 40.9% patients in the study had schizophrenia and other psychotic disorders (N = 31468) followed by major depressive disorder (N = 18141, 23.6%), mood disorder NOS (N = 6328, 8.2%), bipolar disorder--manic type (N = 6210, 8.1%), bipolar disorder NOS (N = 5323, 6.9%), bipolar disorder--depressive type (N = 5175, 6.7%), and depressive disorder NOS (N = 4376, 5.7%) as the primary psychiatric diagnosis for admission.

3.2. Demographic predictors of TD {#sec3.2}
---------------------------------

Majority of the patients with TD were aged 35--49 years (26.5%) and 50--64 years (40%). So, advanced age is a risk factor for increased rates of TD. No significant gender difference for higher odds of TD was seen (OR = 1.033; 95% CI 1.012--1.053; P = .002). A higher proportion of African Americans were noted in the TD group as compared to the non-TD group (17.7% vs. 8.7%). They had two-fold higher odds of TD (OR = 1.812; 95% CI 1.737--1.890; P \< .001). Majority of the patients with TD were covered by Medicare (45.1%), followed by Medicaid (25.4%) and private health insurance (20%). More than 60% of the patients with TD were from low-income families (household income \<50^th^ percentile). The demographic differences between patients with and without TD are shown in [Table 1](#tbl1){ref-type="table"}.Table 1Demographic distribution.Table 1CharacteristicTD (-)\
N = 38640TD (+)\
N = 38382Pearson χ^2^ TestN%N%χ^2^ statisticP valueAge18--34 years891023.1884523.0.039.99835--49 years1025026.51016726.550--64 years1542539.91534840.0≥65 years405510.5402210.5GenderMale1873548.51934450.428.601\<.001Female1990551.51902749.6RaceCaucasian3026079.42359769.41649.648\<.001African American33158.7600617.7Hispanic32708.624137.1Other12703.319685.8Health insuranceMedicare1522539.51727245.1466.033\<.001Medicaid1065027.6971525.4Private963025.0766920.0Self-pay13553.518294.8Other17204.518114.7Median household income0--25^th^ Percentile782520.81264234.23468.591\<.00126^th^ -- 50^th^ Percentile745019.81015127.451^st^ -- 75^th^ Percentile1106529.3773120.976^th^ -- 100^th^ Percentile1137030.2648717.5[^1]

3.3. Comorbidity-related risk factors of TD {#sec3.3}
-------------------------------------------

Regression model controlled age, gender, race and median household income was used to evaluate the odds ratio (OR) in patients with TD. These patients had a higher risk of cardio-metabolic comorbidities including diabetes (OR = 1.542), hypertension (OR = 1.776) and obesity (OR = 1.613) as shown in [Table 2](#tbl2){ref-type="table"}. Patients with TD had higher odds of concurrent tobacco abuse (OR = 1.967) and drug abuse (OR = 1.507) compared to those without TD.Table 2Association of comorbidities in patients with tardive dyskinesia.Table 2ComorbidityTD (-)TD (+)PLogistic regressionN%N%OR95% CIP valueDiabetes540514.0544514.2.4291.5421.414--1.680\<.001Hypertension1308033.91386736.1\<.0011.7761.635--1.930\<.001Obesity38309.938009.9.9571.6131.481--1.756\<.001Tobacco use677517.5852522.2\<.0011.9671.843--2.099\<.001Alcohol abuse1092028.3645716.8\<.0011.030.954--1.111.450Drug abuse1270032.9958125.0\<.0011.5071.403--1.619\<.001[^2][^3]

3.4. Clinical characteristics and hospital outcomes {#sec3.4}
---------------------------------------------------

Patients with diagnosis of schizophrenia and other psychotic disorders had approximately five-fold higher odds of TD (OR = 4.643, 95% CI 4.271--5.047, P \< .001) followed by those with bipolar disorder--depressive type (OR = 4.171, 95% CI 3.772--4.613, P \< .001) and bipolar disorder--manic type (OR = 3.712, 95% CI 3.368--4.092, P \< .001). Majority of the patients admitted to the hospital for the psychiatric illness had a moderate loss of function. Although, patients with TD have a roughly six-folds higher odds of severe disability due to a major loss of function compared to those patients without TD (OR = 5.755, 95% CI 5.207--6.361, P \< .001). The mean LOS per admission was 12.8 days (95% CI 12.696--12.991) in patients with TD which was higher compared to patients without TD (9.7 days; 95% CI 9.596--9.891). The mean total charges per admission was \$35,598 (95% CI 34897--36299) in patients with TD which was much higher than patients without TD (\$22784; 95% CI 22087--23481). Patients with TD had higher odds of longer hospitalization of more than seven days (median LOS of the study population) (OR = 3.502, 95% CI 3.224--3.804, P \< .001) and higher hospitalization total charges of above the median \$16,085 (OR = 3.756, 95% CI 3.457--4.081, P \< .001) compared to the patients without TD.

A lesser number of patients with TD (79.4%) were discharged routinely to their home as compared to 84.9% of the patients without TD. Patients with TD had highest likelihood of disposition to skilled nursing facility (SNF)/intermediate nursing facility (INF) (OR = 5.358, 95% CI 4.865--5.901, P \< .001) and short-term hospital (OR = 3.294, 95% CI 2.924--3.710, P \< .001). The distribution of hospital outcomes is shown in [Table 3](#tbl3){ref-type="table"}.Table 3Primary psychiatric diagnosis, illness severity and hospital outcomes.Table 3CharacteristicTD (-)TD (+)Pearson χ^2^ TestN%N%χ^2^ statisticP valuePrimary psychiatric diagnosisBipolar disorder, manic type27607.134509.07627.834\<.001Bipolar disorder, depressive type21855.729907.8Bipolar disorder, NOS29407.623836.2MDD1160530.0653617.0Depressive disorder NOS30507.913263.5Mood disorder NOS511513.212133.2Schizophrenia & other psychotic disorders1098528.42048353.4Severity of illnessMinor loss of function1414536.6703018.33250.218\<.001Moderate loss of function2153555.72717470.8Major loss of function29607.7417710.9Hospital LOS and cost\>7 days (median)1598041.42004852.2914.985\<.001\> \$16085 (median)1689543.72136955.71100.003\<.001Disposition of patientRoutine3270084.93044079.4470.071\<.001Short-term hospital11703.013243.5SNF/INF29007.5552614.4Home healthcare12803.37161.9AMA4451.2315.8[^4]

Based on a multiple linear regression model, co-diagnosis of TD was an independent risk factor for extended hospitalization and was associated with a 6.36-day increase in LOS and an increase of \$20,415 in total charges during hospitalization. Other factors associated with higher hospital charges included older patient age (\>50 years), females, Caucasian race, and severe morbidity. [Table 4](#tbl4){ref-type="table"} summarizes the predictors of LOS and cost of hospitalization in psychiatric inpatients.Table 4Predictors of LOS and cost for adult psychiatric inpatients.Table 4PredictorLOS (days)95% CICost (\$)95% CITardive Dyskinesia6.366.174--6.5502041519537--21293Age \>50 years4.133.921--4.335102629296--11227Female2.922.723--3.12463785442--7314Caucasian3.813.622--4.00185187635--9401Severe Morbidity6.876.504--7.2441969517966--21424[^5]

4. Discussion {#sec4}
=============

Our study of psychiatric inpatients with TD reveals the demographic and medical risk factors associated with TD and the impact of TD on the psychiatric hospitalization and related outcomes. Previous studies conducted to evaluate the relationship of TD with age have revealed strong predisposition of TD in elder patients above 60 years ([@bib24]; [@bib27]). Owing to the increased vulnerability of TD, careful use of neuroleptics is warranted in the elderly population ([@bib20]). In our study, almost half of the patients with TD were middle-aged adults (40--60 years), and there was an age-related increase in the prevalence of TD in the inpatient study population. Our findings support the previous evidence that advanced age is a risk factor for the development of TD ([@bib16]). Our study did not find a significant gender difference in psychiatric inpatients with TD. On the contrary, a literature review on 76 selected studies on the prevalence of TD conducted by Yassa R et al. found that there was an increased preponderance and intensity of TD in women (26.6%) than in men (21.6%) ([@bib37]). This review ([@bib37]) comprised of studies from four continents including North America, Africa, Asia, and Europe, whereas our study sample comprises of inpatients in the United States only and the increasing use of antipsychotics in the last few decades especially in those with mood disorders may account for lack of gender difference.

The prevalence of TD was highest among Caucasian, yet African Americans had two-fold higher odds of TD compared to not having TD which supports prior findings. African Americans tend to develop TD after minimal exposure to antipsychotics for a short duration compared to other races ([@bib16]). Our results yielded an interesting linear relationship of TD with the income as increasing household income had a decreasing trend in the prevalence of TD and vice versa. In addition to age, gender, and race, other factors such as longer duration of illness and gene polymorphisms involving antipsychotic metabolism and dopamine functioning are some of the unmodifiable and illness related risk factors associated with TD ([@bib28]; [@bib29]; [@bib33]). These factors were not analyzed in our study due to the nature of available data and the scope of our study.

Prior studies have concluded that diabetes mellitus, cigarette smoking, alcohol, and drug abuse are some of the modifiable risk factors associated with the higher risk of development of TD ([@bib28]; [@bib29]; [@bib33]). In our study, patients with TD had two-fold higher odds of comorbid hypertension, and this may be due to antipsychotic-related metabolic dysfunction in psychiatric inpatients. Two prospective studies on diabetic and non-diabetic participants on chlorpromazine state that an increased prevalence and severity of TD was seen with diabetes ([@bib13]; [@bib14]). Our study results suggest that patients with TD were at 1.5 times higher odds of having diabetes as compared to the other psychiatric inpatients without TD. The N-Methyl-D-Aspartate system can be possibly implicated in the association of TD and drug abuse ([@bib2]). Alcohol abuse was associated with severe orofacial dyskinesia and acts as an added risk factor for the development of TD as per past survey ([@bib12]; [@bib36]). In our study, TD patients had 1.5-fold higher risk of co-existing drug abuse, but the odds for comorbid alcohol abuse was lower in TD patients as the prevalence of alcohol abuse was much lower (16.8%) than that seen in patients without TD (28.3%).

Schizophrenia patients may develop TD eventually in the advancement of the disease irrespective of the use of antipsychotics ([@bib33]; [@bib36]). Based on the age and duration of illness, patients with schizophrenia and on antipsychotics have a 4%--40% chance of developing TD ([@bib33]). In our study, patients with a primary diagnosis of schizophrenia and other psychotic disorders had five-fold higher odds of TD, and the regression model was controlled for demographic characteristics and comorbidities. Waddington JL et al. ([@bib31]) reported that long-term exposure to antipsychotics leads to chronic, deteriorating, psychiatric illness and also leads to the occurrence of movement disorder. Patients with TD constitute a physically deprived group due to broader disease syndrome including cardiovascular disorders and morbidity ([@bib39]). Our study supports this fact as patients with TD had about six-folds higher odds of severe disability due to major loss of function compared to patients without TD. It must be noted that we are not able to comment on the duration of psychotic illness and exposure to antipsychotic medications due to the limitations of the NIS dataset used in our study.

A study conducted by [@bib5] in a rehabilitation center concluded that presence of TD was associated with a poorer quality of life which was related to psychiatric symptom severity, illness duration and increased the length of previous hospitalization ([@bib5]). Our study results suggest that patients with TD had roughly four-fold likelihood of extended hospitalization and higher hospitalization total charges compared to patients without TD. Even past studies support this fact as TD patients had more extended hospitalization due to severe morbidity ([@bib5]; [@bib36]). In multiple linear regression model of our study, inpatients with TD had about 6.36-day increase in LOS and an increase of \$20,415 in total charges per hospital admission. As patients with TD had severe morbidity or disability ([@bib5]; [@bib31]; [@bib39]), they had higher odds of adverse disposition (SNF/INF and short-term hospital) compared to patients without TD.

Our study has some limitations. The NIS is an administrative database and lacks the patient level data needed to make accurate clinical associations. Further, such retrospective studies are always subject to selection bias, which might be highlighted by the moderate sensitivity of diagnostic codes for TD and primary psychiatric diagnoses. Another limitation was the lack of information on the type of antipsychotics administered during hospitalization, total cumulative amount of antipsychotics, past medication history and the duration of psychiatric illnesses. Therefore, this study does not provide an association of comorbidities and hospital outcomes about first versus second-generation antipsychotics. Due to the cross-sectional design of this study we were not able to address longitudinal treatment process including switching to another class of antipsychotics which may affect the propensity to develop TD. Severity of the condition that is mentioned in this study is based APR-DRGs variable in the NIS, and we were not able assess the clinical severity of TD based on clinical scales. We were not able to account for re-hospitalizations, given the nature of the database, although they add to the total inpatient burden. Despite these potential limitations, the NIS database ([@bib19]) provides a unique population-based perspective on disease associations with systematic and temporal factors and provides a rationale for further in-depth studies. The biggest strength of our study lies in the national representation of the dataset, with a uniform collection of data, through ICD-9-CM codes over five years. This is the first study, to our knowledge, to report the association of various comorbidities and risk of adverse hospital outcomes in psychiatric inpatients with TD. Using the NIS, we were able to obtain a large sample size as we included 77,022 patients admitted for primary psychiatric diagnoses. This dataset is subject to minimal reporting bias, and all information is coded independently of the individual practitioner, making it a more reliable source.

In the inpatient settings, TD was highly associated with advancing age, lower socioeconomic status and African-American. Psychiatric inpatients with TD have greater severity of illness, and those with schizophrenia and bipolar disorders are at the highest risk of TD. Presence of TD portends poor hospital outcomes including increased LOS and total charges during hospitalization and more indigent post-management disposition. More systematic research is warranted to implement clinical strategies to both prevent TD and optimize inpatient outcomes in psychiatric patients with TD.
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[^1]: Difference between groups measured by Pearson\'s Chi-squared Test. Significant P values ≤.0001 at 95% Confidence Interval. Components may not add up to the rounded sum due to weighting and rounding or missing data. TD: Tardive Dyskinesia.

[^2]: Differences between groups conducted by Pearson\'s Chi-squared Test. Significant P values ≤.0001 at 95% Confidence Interval. Components may not add up to the rounded sum due to weighting and rounding or missing data.

[^3]: Odds Ratio generated by multinomial logistic regression model were adjusted for age, gender, race and median-household income. Reference category for this model was patients without TD (-). TD: Tardive Dyskinesia; OR: Odds Ratio; CI: Confidence Interval.

[^4]: Differences between groups conducted by Pearson\'s Chi-squared Test. Significant P values ≤.0001 at 95% Confidence Interval. Components may not add up to the rounded sum due to weighting and rounding or missing data. TD: Tardive Dyskinesia; MDD: Major Depressive Disorder; NOS: not otherwise specified; LOS: length of stay; SNF: skilled nursing facility; INF: intermediate nursing facility; AMA: against medical advice.

[^5]: Significant P values ≤.0001 at 95% Confidence Interval (CI). The estimated increase in length of hospital stay and cost was generated by linear regression model. LOS: length of stay.
